Combinatorial prediction of therapeutic perturbations using causally inspired neural networks
Phenotype-driven approaches identify disease-counteracting compounds by analysing the phenotypic signatures that distinguish diseased from healthy states. Here we introduce PDGrapher, a causally inspired graph neural network model that predicts combinatorial perturbagens (sets of therapeutic targets) capable of reversing disease phenotypes. Unlike methods that learn how perturbations alter phenotypes, PDGrapher solves the inverse problem and predicts the perturbagens needed to achieve a desired response by embedding disease cell states into networks, learning a latent representation of these states, and identifying optimal combinatorial perturbations. In experiments in nine cell lines with chemical perturbations, PDGrapher identifies effective perturbagens in more testing samples than competing methods. It also shows competitive performance on ten genetic perturbation datasets. An advantage of PDGrapher is its direct prediction, in contrast to the indirect and computationally intensive approach common in phenotype-driven models. It trains up to 25× faster than existing methods, providing a fast approach for identifying therapeutic perturbations and advancing phenotype-driven drug discovery.
Authors
- Michael M. Bronstein (ORCID: https://orcid.org/0000-0002-1262-7252)
- Guadalupe Gonzalez (ORCID: https://orcid.org/0000-0002-7650-3056)
- Isuru S. Herath (ORCID: https://orcid.org/0009-0001-1256-2591)
- Kirill Veselkov (ORCID: https://orcid.org/0000-0002-1164-0359)
- Marinka Žitnik (ORCID: https://orcid.org/0000-0001-8530-7228)
- Xiang Lin (ORCID: https://orcid.org/0000-0003-2789-4449)
Institutions
- Broad Institute (US)
- Roche (Switzerland) (CH)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Harvard University (US)
- Cornell University (US)
- Yale University (US)
- University of Oxford (GB)
- Dana-Farber/Harvard Cancer Center (US)
- Artificial Intelligence in Medicine (Canada) (CA)
- Imperial College London (GB)
- Carnegie Mellon University (US)
- Voith (United States) (US)
Publication Details
- Journal
- Nature Biomedical Engineering
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1038/s41551-025-01481-x
- Citations
- 9
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 13.54
Funders
- National Science Foundation
- Bill and Melinda Gates Foundation
- Pfizer
- AstraZeneca
- Sanofi
- Harvard University
- National Institutes of Health
- Advanced Research Projects Agency
- Harvard Data Science Initiative, Harvard University